Trulicity ® (dulaglutide)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: (England, Scotland, Wales) or (Northern Ireland).

Can Trulicity® (dulaglutide) be used in patients with COVID-19?

Lilly has not studied the use of dulaglutide in patients with COVID-19 nor in patients at risk of contracting COVID-19.


Can dulaglutide be used in patients with respiratory infections?

According to the dulaglutide label, respiratory infections

  • are not listed as a warning or precautions for use of dulaglutide, and
  • are not listed as adverse events.1

Use your clinical judgment to choose the most appropriate approach to treat Type 2 Diabetes patients with confirmed or suspected COVID-19.

Infectious Disease Resources for COVID-19

For current information on COVID-19, please refer to


1Trulicity [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2Coronavirus disease (COVID-19) outbreak. European web page of the World Health Organization. Accessed March 20, 2020.

3International Diabetes Federation Europe. COVID-19 outbreak: guidance for people with diabetes. Accessed March 18, 2020

4COVID-19. European Centre for Disease Prevention and Control. Accessed March 20, 2020.

Date of Last Review: 16 March 2020

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request